Assertio (ASRT) Competitors $0.66 +0.00 (+0.43%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.66 -0.01 (-0.89%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. TVRD, LFCR, ZYBT, ESPR, DBVT, MDWD, YMAB, TIL, SLRN, and IMABShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Cara Therapeutics (TVRD), Lifecore Biomedical (LFCR), Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), DBV Technologies (DBVT), MediWound (MDWD), Y-mAbs Therapeutics (YMAB), Instil Bio (TIL), Acelyrin (SLRN), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Cara Therapeutics Lifecore Biomedical Zhengye Biotechnology Esperion Therapeutics DBV Technologies MediWound Y-mAbs Therapeutics Instil Bio Acelyrin I-Mab Cara Therapeutics (NASDAQ:TVRD) and Assertio (NASDAQ:ASRT) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation. Do analysts prefer TVRD or ASRT? Cara Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 149.52%. Assertio has a consensus target price of $2.75, indicating a potential upside of 316.10%. Given Assertio's higher possible upside, analysts clearly believe Assertio is more favorable than Cara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in TVRD or ASRT? 44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by company insiders. Comparatively, 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer TVRD or ASRT? Assertio received 113 more outperform votes than Cara Therapeutics when rated by MarketBeat users. Likewise, 59.69% of users gave Assertio an outperform vote while only 50.00% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes150.00% Underperform Votes150.00% AssertioOutperform Votes11459.69% Underperform Votes7740.31% Does the media favor TVRD or ASRT? In the previous week, Cara Therapeutics had 1 more articles in the media than Assertio. MarketBeat recorded 2 mentions for Cara Therapeutics and 1 mentions for Assertio. Assertio's average media sentiment score of 1.87 beat Cara Therapeutics' score of 0.00 indicating that Assertio is being referred to more favorably in the news media. Company Overall Sentiment Cara Therapeutics Neutral Assertio Very Positive Is TVRD or ASRT more profitable? Cara Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara TherapeuticsN/A N/A N/A Assertio -54.46%3.79%1.81% Which has preferable valuation and earnings, TVRD or ASRT? Cara Therapeutics has higher earnings, but lower revenue than Assertio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara TherapeuticsN/AN/AN/AN/AN/AAssertio$119.00M0.53-$331.94M-$0.32-2.07 Which has more risk & volatility, TVRD or ASRT? Cara Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. SummaryAssertio beats Cara Therapeutics on 11 of the 13 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.30M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-0.918.7927.2020.17Price / Sales0.53263.51412.92161.94Price / Cash1.1265.8538.2534.64Price / Book0.456.677.114.72Net Income-$331.94M$143.49M$3.23B$247.80M7 Day Performance-0.86%5.15%3.77%2.76%1 Month Performance8.11%15.43%13.33%9.71%1 Year Performance-38.81%6.02%32.03%14.51% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio1.4415 of 5 stars$0.66+0.4%$2.75+316.1%-39.9%$63.30M$119.00M-0.9120Positive NewsTVRDCara TherapeuticsN/A$26.90-5.6%$65.00+141.6%N/A$251.81MN/A0.0080Gap UpHigh Trading VolumeLFCRLifecore Biomedical1.6309 of 5 stars$6.78-1.0%$8.00+18.0%+16.3%$251.03M$130.31M-12.11690ZYBTZhengye BiotechnologyN/A$5.16-12.7%N/AN/A$243.38M$189.75M0.00278Gap UpESPREsperion Therapeutics4.081 of 5 stars$1.20-1.6%$6.25+420.8%-58.1%$237.84M$259.57M-1.88200Options VolumeDBVTDBV Technologies3.1141 of 5 stars$8.68-4.9%$14.75+69.9%+73.1%$237.75M$15.73M-1.9380Positive NewsGap UpMDWDMediWound2.0218 of 5 stars$21.46-0.6%$31.80+48.2%+29.3%$231.94M$19.21M-7.4080Positive NewsYMABY-mAbs Therapeutics3.767 of 5 stars$5.08-3.6%$15.60+207.1%-57.7%$230.04M$88.66M-9.41150Positive NewsAnalyst RevisionTILInstil Bio3.1489 of 5 stars$35.07+6.6%$119.00+239.3%+258.7%$230.02MN/A-3.03410Gap UpHigh Trading VolumeSLRNAcelyrin2.9512 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135IMABI-Mab2.9346 of 5 stars$2.80+14.3%$5.50+96.4%+42.3%$228.65M$3.27M0.00380Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Cara Therapeutics Competitors Lifecore Biomedical Competitors Zhengye Biotechnology Competitors Esperion Therapeutics Competitors DBV Technologies Competitors MediWound Competitors Y-mAbs Therapeutics Competitors Instil Bio Competitors Acelyrin Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASRT Stock Free ASRT Stock Alerts